Muscle Invasive Bladder Cancer Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight
(Albany, United States) As per DelveInsight’s assessment, globally, Muscle Invasive Bladder Cancer pipeline constitutes 10+ key companies continuously working towards developing 10+ Muscle Invasive Bladder Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Muscle Invasive Bladder Cancer Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Muscle Invasive Bladder Cancer Market.
The Muscle Invasive Bladder Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Muscle Invasive Bladder Cancer Pipeline Analysis
Some of the key takeaways from the Muscle Invasive Bladder Cancer Pipeline Report:
- Muscle Invasive Bladder Cancer Companies across the globe are diligently working toward developing novel Muscle Invasive Bladder Cancer treatment therapies with a considerable amount of success over the years.
- Muscle Invasive Bladder Cancer companies working in the treatment market are Merck Sharp & Dohme LLC, Aura Biosciences, Janssen Research & Development, LLC, Asieris Pharmaceuticals, RemeGen Co., Ltd. and others, are developing therapies for the Muscle Invasive Bladder Cancer treatment
- Emerging Muscle Invasive Bladder Cancer therapies such as AU-011, TAR-200, KEYNOTE-905/EV-303, RC48-ADC Combined with JS001, and others are expected to have a significant impact on the Muscle Invasive Bladder Cancer market in the coming years.
- In June 2024, Janssen Research & Development announced results of a Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
- In May 2024, Merck Sharp & Dohme LLC announced results of a Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
- In February 2024, RemeGen Co., Ltd announced results of an Open-label, Single-arm, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of RC48-ADC Combined With JS001 in Perioperative Treatment of Muscle-Invasive Bladder Cancer
Muscle Invasive Bladder Cancer Overview
Muscle-invasive bladder cancer (MIBC) is a serious and aggressive form of bladder cancer where the tumor penetrates into the muscle layer of the bladder wall. It accounts for approximately 25% of all bladder cancer cases and is more challenging to treat compared to non-muscle-invasive forms.
Risk factors for MIBC include smoking, exposure to industrial chemicals, chronic bladder inflammation, and certain genetic predispositions. Symptoms often include hematuria (blood in the urine), frequent urination, pelvic pain, and urinary urgency.
Diagnosis typically involves a combination of cystoscopy (a procedure to look inside the bladder with a camera), imaging studies such as CT or MRI scans, and biopsy to confirm the presence and extent of the cancer. Staging of the disease is crucial to determine the appropriate treatment approach.
Treatment for MIBC usually involves a multimodal strategy. The standard treatment is radical cystectomy, which involves the surgical removal of the bladder and surrounding tissues. This is often combined with neoadjuvant chemotherapy (chemotherapy given before surgery) to shrink the tumor and improve surgical outcomes. In some cases, radiation therapy may be used, either in conjunction with surgery or as an alternative for patients who cannot undergo surgery.
Despite aggressive treatment, MIBC has a high risk of recurrence and metastasis. Thus, ongoing follow-up and monitoring are essential. Research into new therapies, including immunotherapy and targeted treatments, offers hope for improved outcomes in the future.
Get a Free Sample PDF Report to know more about Muscle Invasive Bladder Cancer Pipeline Therapeutic Assessment- Muscle Invasive Bladder Cancer Treatment Market
Muscle Invasive Bladder Cancer Route of Administration
Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Muscle Invasive Bladder Cancer Molecule Type
Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types, such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Muscle Invasive Bladder Cancer Pipeline Therapeutics Assessment
- Muscle Invasive Bladder Cancer Assessment by Product Type
- Muscle Invasive Bladder Cancer By Stage and Product Type
- Muscle Invasive Bladder Cancer Assessment by Route of Administration
- Muscle Invasive Bladder Cancer By Stage and Route of Administration
- Muscle Invasive Bladder Cancer Assessment by Molecule Type
- Muscle Invasive Bladder Cancer by Stage and Molecule Type
DelveInsight’s Muscle Invasive Bladder Cancer Pipeline Report covers around 10+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Muscle Invasive Bladder Cancer product details are provided in the report. Download the Muscle Invasive Bladder Cancer pipeline report to learn more about the emerging Muscle Invasive Bladder Cancer therapies- Muscle Invasive Bladder Cancer Therapeutics Market
Muscle Invasive Bladder Cancer Pipeline Analysis:
The Muscle Invasive Bladder Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Muscle Invasive Bladder Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Muscle Invasive Bladder Cancer Treatment.
- Muscle Invasive Bladder Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Muscle Invasive Bladder Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Muscle Invasive Bladder Cancer market.
Download Sample PDF Report to know more about Muscle Invasive Bladder Cancer drugs and therapies- Muscle Invasive Bladder Cancer Clinical Trials and FDA Approvals
Scope of Muscle Invasive Bladder Cancer Pipeline Drug Insight
- Coverage: Global
- Key Muscle Invasive Bladder Cancer Companies: Afimmune, MediciNova, Mariposa Health Limited, MedWell Laboratories, BioElectron Technology, CSPC Ouyi Pharmaceutical, Veralox Therapeutics, Qurient Therapeutics, PTC Therapeutics and others.
- Key Muscle Invasive Bladder Cancer Therapies: Epeleuton, Tipelukast, TA 270, MW 001, PTC 857, Baicalein, VLX 1005, Research programme: 5-Muscle Invasive Bladder Cancer Inhibitor (LOX Inhibitor), and others.
- Muscle Invasive Bladder Cancer Therapeutic Assessment: Muscle Invasive Bladder Cancer current marketed and Muscle Invasive Bladder Cancer emerging therapies
- Muscle Invasive Bladder Cancer Market Dynamics: Muscle Invasive Bladder Cancer market drivers and Muscle Invasive Bladder Cancer market barriers
Request for Sample PDF Report for Muscle Invasive Bladder Cancer Pipeline Assessment and clinical trials – Muscle Invasive Bladder Cancer Drugs and Therapies
Table of Contents
- Muscle Invasive Bladder Cancer Report Introduction
- Muscle Invasive Bladder Cancer Executive Summary
- Muscle Invasive Bladder Cancer Overview
- Muscle Invasive Bladder Cancer- Analytical Perspective In-depth Commercial Assessment
- Muscle Invasive Bladder Cancer Pipeline Therapeutics
- Muscle Invasive Bladder Cancer Late Stage Products (Phase II/III)
- Muscle Invasive Bladder Cancer Mid Stage Products (Phase II)
- Muscle Invasive Bladder Cancer Early Stage Products (Phase I)
- Muscle Invasive Bladder Cancer Preclinical Stage Products
- Muscle Invasive Bladder Cancer Therapeutics Assessment
- Muscle Invasive Bladder Cancer Inactive Products
- Company-University Collaborations (Licensing/Partnering) Analysis
- Muscle Invasive Bladder Cancer Companies
- Muscle Invasive Bladder Cancer Key Products
- Muscle Invasive Bladder Cancer Unmet Needs
- Muscle Invasive Bladder Cancer Market Drivers and Barriers
- Muscle Invasive Bladder Cancer Future Perspectives and Conclusion
- Muscle Invasive Bladder Cancer Analyst Views
- Appendix
- About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
